# Immunological Variables Associated to ICI Toxicity in Cancer Patients

> **NCT05429866** · PHASE2 · UNKNOWN · sponsor: **Jules Bordet Institute** · enrollment: 441 (estimated)

## Conditions studied

- Breast Cancer
- Melanoma
- Non Small Cell Lung Cancer
- Non-melanoma Skin Cancer
- Gastrointestinal Cancer
- Head and Neck Cancer
- Renal Cell Carcinoma
- Small Cell Lung Cancer
- Mesothelioma, Malignant
- Bladder Cancer
- Merkel Cell Carcinoma
- Hepatocellular Carcinoma
- MSI-H Colorectal Cancer

## Interventions

- **DRUG:** Checkpoint Blockade, Immune

## Key facts

- **NCT ID:** NCT05429866
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 441 (ESTIMATED)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429866, "Immunological Variables Associated to ICI Toxicity in Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05429866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*